Nov 4, 4:10 PM ET
Vir Biotechnology reported third quarter 2026 results with a net loss of $96.3 million, or $0.57 per share, compared with $163.1 million, or $1.17 per share, a year earlier. The prior-year period included a non-recurring $75.0 million milestone expense, and total revenues were a loss of $188 thousand versus $240 thousand of revenue in the prior year. The company also reported topline Phase 3 ECLIPSE 1 data for hepatitis delta expected in the fourth quarter of 2026, and said its cash runway extends into the second half of 2028.
- Net loss was $96.3 million, or $0.57 per share, versus $163.1 million, or $1.17 per share, in Q3 2025
- R&D expenses were $80.0 million versus $151.5 million a year earlier, which included a $75.0 million milestone expense
- Cash, cash equivalents and investments were $901.3 million at September 30, 2026, down $106.5 million in the quarter
- Topline ECLIPSE 1 Phase 3 data expected in Q4 2026; company expects cash to fund operations into the second half of 2028
Read the filing on SEC.gov ↗
Oct 28, 8:37 AM ET
Vir Biotechnology's Board increased its size from eight to nine members and appointed Suzanne Topalian, M.D., to fill the new seat, effective October 27, 2026. She also joined the Science and Technology Committee and receives the standard non-employee director compensation, including automatic option and restricted stock unit grants.
- Board expanded from eight to nine members; Dr. Topalian named Class III director through the 2028 annual meeting
- Dr. Topalian appointed to the Science and Technology Committee, effective October 27, 2026
- She received stock option and restricted stock unit awards under the 2019 Equity Incentive Plan on her appointment date
- Company has signed its standard indemnity agreement with Dr. Topalian
Read the filing on SEC.gov ↗
Jan 12, 8:07 AM ET
Vir Biotechnology said it had approximately $781 million in cash, cash equivalents and investments as of December 31, 2025, an unaudited figure, and that this balance is expected to fund operations into the fourth quarter of 2027, which it links to the Norgine licensing agreement and continued financial discipline. It also released updated Phase 2 SOLSTICE data for its chronic hepatitis delta combination therapy, with 88% of participants evaluated through Week 96 reaching undetectable hepatitis delta virus RNA versus 46% on the antibody alone. The filing contains no full-year revenue or profit figures, which the company expects to report in late February 2026.
- Preliminary, unaudited cash, cash equivalents and investments of approximately $781 million as of December 31, 2025; full fourth-quarter and 2025 results expected in late February 2026.
- Cash runway extended into the fourth quarter of 2027, tied by the company to the Norgine license for chronic hepatitis delta in Europe, Australia and New Zealand.
- SOLSTICE Phase 2: undetectable HDV RNA at Week 96 in 88% (21/24) of combination participants versus 46% (11/24) on tobevibart alone.
- Company to present at the J.P. Morgan Healthcare Conference on January 14, 2026, at 3:45 p.m. PT.
Read the filing on SEC.gov ↗
Dec 16, 4:25 PM ET
Vir Biotechnology granted Norgine Pharma UK Limited an exclusive license for commercial rights to its tobevibart and elebsiran combination for chronic hepatitis delta in Europe, Australia and New Zealand. Vir will receive an initial reimbursement of EUR 55 million, is eligible for up to EUR 495 million in milestones, and will earn royalties on net sales in that territory, while the companies share ECLIPSE trial costs. The company says the agreement extends its current cash runway into the fourth quarter of 2027.
- Initial reimbursement payment of EUR 55 million to Vir, with closing for certain non-US jurisdictions subject to regulatory approval
- Eligible for up to EUR 495 million in clinical, regulatory and sales milestones, plus tiered mid-teen to high-twenties percent royalties on net sales in the licensed territory
- Norgine to contribute approximately 25% of go-forward external costs for the ECLIPSE 1, 2 and 3 trials
- Vir retains commercial rights in the United States and other markets outside the Greater China Territory; company expects cash runway into Q4 2027
Read the filing on SEC.gov ↗
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.